Disease-related factors associated with HER2 overexpression include the site of the primary tumor and the Consensus Molecular Classification subtype, with a higher incidence observed in the upper urinary tract and luminal cancers, respectively [87,89]. This evidence concerns the gene ERBB2 and cancer.